Browse by Person

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 3.

Article

Coleman, RE, Collinson, M orcid.org/0000-0003-3568-6455, Gregory, W orcid.org/0000-0003-2641-8416 et al. (20 more authors) (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). Journal of Bone Oncology, 13. pp. 123-135. ISSN 2212-1374

Baird, R, Banks, I, Cameron, D et al. (53 more authors) (2016) An Association of Cancer Physicians’ strategy for improving services and outcomes for cancer patients. Ecancermedicalscience, 10. 608.

Proceedings Paper

Jones, RH, Carucci, M, Casbard, AC et al. (10 more authors) (2019) Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER -positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial. In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology .

This list was generated on Sat Oct 19 16:19:20 2019 BST.